Mirabilis is dedicated to improving the treatment of symptomatic uterine fibroids using its proprietary high-intensity focused ultrasound (HIFU) technology. Founded in 2004, Mirabilis is currently developing a non-invasive system for this purpose, and is conducting clinical studies outside of the United States.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/17/13 | $7,000,000 | Series A-1 |
GSR Ventures | undisclosed |
